Article

Radiation induced non-targeted response: mechanism and potential clinical implications.

Center for Radiological Research, Department of Radiation Oncology, Columbia University Medical Center, Vanderbilt Clinic, New York, USA.
Current Molecular Pharmacology 12/2010; 4(2):96-105. pp.96-105
Source: PubMed

ABSTRACT Generations of students in radiation biology have been taught that heritable biological effects require direct damage to DNA. Radiation-induced non-targeted/bystander effects represent a paradigm shift in our understanding of the radiobiological effects of ionizing radiation in that extranuclear and extracellular effects may also contribute to the biological consequences of exposure to low doses of radiation. Although radiation induced bystander effects have been well documented in a variety of biological systems, including 3D human tissue samples and whole organisms, the mechanism is not known. There is recent evidence that the NF-κB-dependent gene expression of interleukin 8, interleukin 6, cyclooxygenase-2, tumor necrosis factor and interleukin 33 in directly irradiated cells produced the cytokines and prostaglandin E2 with autocrine/paracrine functions, which further activated signaling pathways and induced NF-κB-dependent gene expression in bystander cells. The observations that heritable DNA alterations can be propagated to cells many generations after radiation exposure and that bystander cells exhibit genomic instability in ways similar to directly hit cells indicate that the low dose radiation response is a complex interplay of various modulating factors. The potential implication of the non-targeted response in radiation induced secondary cancer is discussed. A better understanding of the mechanism of the non-targeted effects will be invaluable to assess its clinical relevance and ways in which the bystander phenomenon can be manipulated to increase therapeutic gain in radiotherapy.

1 0
 · 
1 Bookmark
 · 
53 Views
  • Article: Translational approaches to treatment-induced symptoms in cancer patients.
    [show abstract] [hide abstract]
    ABSTRACT: Cancer therapy makes patients sick. The therapies that are available to clinicians allow them to successfully control nausea, emesis and pain. However, this is not the case for a number of other symptoms that include fatigue, distractibility, poor memory, and diminished interest in previously pleasurable activities. These symptoms cluster during the course of cancer therapy and impair patient quality of life, limit therapy options and do not always resolve at the cessation of treatment. It is possible to describe the intensity and temporal features of symptoms and assess their relationship with the inflammatory response that is associated with cancer and cancer therapy. At the preclinical level, sophisticated animal models still need to be deployed to study the causal role of inflammation in specific components of cancer-related symptoms. Various approaches can be optimally combined in a translational symptom research pathway to provide a framework for assessing in a systematic manner the neurobehavioral toxicity of existing and newly developed cancer therapies. Ultimately, this knowledge will allow derivation of mechanism-based interventions to prevent or alleviate cancer-related symptoms.
    Nature Reviews Clinical Oncology 05/2012; 9(7):414-26. · 11.96 Impact Factor

Keywords

biological consequences
 
bystander cells
 
bystander cells exhibit genomic instability
 
bystander phenomenon
 
direct damage
 
heritable biological effects
 
increase therapeutic gain
 
induced NF-κB-dependent gene expression
 
interleukin 33
 
irradiated cells
 
NF-κB-dependent gene expression
 
prostaglandin E2
 
radiation biology
 
radiation exposure
 
radiation induced bystander effects
 
radiation induced secondary cancer
 
Radiation-induced non-targeted/bystander effects
 
tumor necrosis factor
 
various modulating factors
 
whole organisms